文献速递中医内科中药与中成药合理使用

中药联合西药与单用西药治疗原发性高血压的系统评价与Meta分析

Integrated Chinese herbal medicine with Western Medicine versus Western Medicine in the effectiveness of primary hypertension treatment: A systematic review and meta-analysis of randomized controlled trials.
PubMed 文献 · J Ethnopharmacol · 2022-09-10

该系统评价与Meta分析纳入29项随机对照试验共2623例原发性高血压患者,比较中药联合西药与单用西药的有效性和安全性。结果显示联合治疗在临床有效率、显著有效率和降低收缩压与舒张压方面均优于单用西药,且未报告严重不良反应。

要点

  • 中药联合西药较单用西药提高原发性高血压临床有效率(RR 1.23)和显著有效率(RR 1.66)。
  • 联合治疗降低收缩压(MD 7.91 mmHg)和舒张压(MD 5.46 mmHg),差异有统计学意义。
  • 未报告严重不良反应,无患者因严重不良事件退出治疗。

核心结论

  • 与单用西药相比,中药联合西药治疗原发性高血压可显著提高临床疗效并降低收缩压和舒张压,且未见严重不良反应。

研究设计与样本

  • 系统评价与Meta分析,检索PubMed、COCHRANE、EMBASE、Ovid、CNKI、VIP、Wanfang和CBM数据库,纳入29项随机对照试验共2623例原发性高血压患者。
  • 采用Cochrane偏倚风险评估工具评价质量,RevMan 5.4进行Meta分析。
  • 临床有效和显著有效的判定依据《中药新药临床研究指导原则》。

主要发现

  • 联合治疗组临床有效率显著高于单用西药组(RR 1.23,95% CI [1.17, 1.30],P < 0.00001)。
  • 联合治疗组显著有效率显著高于单用西药组(RR 1.66,95% CI [1.52, 1.80],P < 0.00001)。
  • 联合治疗组舒张压降低优于单用西药组(MD 5.46 mmHg,95% CI [3.88, 6.43],P < 0.00001)。
  • 亚组分析基于干预类型、治疗疗程和中药方剂进行,结果显示联合治疗均具有显著性。

关键数值与推荐

  • 临床有效:RR 1.23,95% CI [1.17, 1.30],P < 0.00001,联合治疗优于单用西药。
  • 显著有效:RR 1.66,95% CI [1.52, 1.80],P < 0.00001,联合治疗优于单用西药。
  • 舒张压降低:MD 5.46 mmHg,95% CI [3.88, 6.43],P < 0.00001,联合治疗优于单用西药。

临床怎么用

  • 对于原发性高血压患者,在单用西药基础上联合中药可能进一步提高降压疗效和临床有效率。
  • 联合治疗未报告严重不良反应,但需结合患者个体情况辨证选用中药方剂。
  • 现有证据质量有限,临床应用时应关注患者耐受性和血压监测。

局限性

  • 纳入的随机对照试验证据质量不足,需要大样本、高质量、长疗程和长期随访的随机对照试验进一步验证。
  • 原文未报告纳入研究的具体偏倚风险分布和异质性指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Integrated Chinese herbal medicine (CHM) and Western Medicine (WM) treatments have been used for primary hypertension (PHTN) patients in China. Currently, there are many randomized control trials (RCTs) published regarding the effect of CHM and WM on PHTN, which indicated that combining Chinese with WM was effective and safe for PHTN when compared with WM alone, but the quality of evidence was insufficient, and there is no clear information and summary are available for these RCTs assessing the effectiveness of CHM with WM versus WM in patients with PHTN. OBJECTIVES: This systematic study and meta-analysis aimed to evaluate the effectiveness and safety of CHM combined with WM in comparison with WM in reducing systolic and diastolic blood pressure for patients with PHTN. METHODS: The information of this study was searched from electronic databases (PubMed, COCHRANE, EMBASE, Ovid, CNKI, VIP, Wanfang, and CBM). The markedly effective and effective terms were according to Guiding Principles for Clinical Research of New Chinese Medicines. Two investigators independently reviewed each trial. The Cochrane risk of bias assessment tool was used for quality assessment, and RevMan 5.4 was used for meta-analysis. RESULTS: In this study, a total of 29 studies that included 2623 patients were recorded. The study results displayed that the clinical effectiveness in the treatment of hypertension patients from the integrated medicines was considerably higher than that with WM alone, clinical effective (RR 1.23, 95% CI [1.17, 1.30], P < 0.00001), and markedly effective (ME) in the patients (RR 1.66, 95% CI [1.52, 1.80], and P < 0.00001). Random effect in SBP (MD 7.91 mmHg,[6.00, 983], P < 0.00001) and DBP (MD 5.46 mmHg, [3.88, 6.43], P < 0.00001), a subgroup analysis was carried out based on the type of intervention, duration of treatment, and CHM formulas that showed significance. Furthermore, no severe side effects were reported, and no patients stopped treatment or withdrawal due to any severe adverse events. CONCLUSION: Compared to WM alone, the therapeutic effectiveness of CHM combined with WM is significantly improved in the treatment of hypertension. Additionally, CHM with WM may safely and efficiently lower systolic blood pressure (SBP) and diastolic blood pressure (DBP) in individuals with PHTN. However, rigorous randomized controlled trials with a large sample, high quality, long duration of treatment, and follow-up are recommended to strengthen this clinical evidence.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Mohammed SAD, Hanxing L, Fang L, et al. Integrated Chinese herbal medicine with Western Medicine versus Western Medicine in the effectiveness of primary hypertension treatment: A systematic review and meta-analysis of randomized controlled trials. J Ethnopharmacol. 2022. PMID: 36096347. doi:10.1016/j.jep.2022.115703

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。